A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS), Trial ID 7517-CL-0101

试验摘要

The purpose of this study is to evaluate the safety and tolerability and to determine the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) of ASP7517.

This study will also evaluate the clinical response of ASP7517 as well as other measures of anticancer activity of ASP7517.

获取更多信息

关于正在招募参与者的 A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)，您是否想了解更多临床试验中心相关信息？请在右侧填写您的信息联系我们，我们将予以回复。

地点

联系我们

正在招募

研究中心 JP81004

Maebashi, 群马, 日本

联系我们

正在招募

研究中心 JP81007

神户, 兵库县, 日本

联系我们

正在招募

研究中心 JP81008

冈山, 冈山, 日本

联系我们

正在招募

研究中心 JP81005

名古屋, 爱知, 日本

联系我们

正在招募

研究中心 JP81001

Shinagawa, 东京, 日本

联系我们

正在招募

研究中心 JP81002

福冈, 福冈, 日本

联系我们

正在招募

研究中心 JP81009

Yoshida-gun, Fukui, 日本

联系我们

正在招募

研究中心 JP81010

Gifu, Gifu, 日本

联系我们

正在招募

研究中心 JP81011

大阪, 大阪, 日本

联系我们

正在招募

研究中心 JP81013

Isehara, 神奈川, 日本

联系我们

正在招募

研究中心 JP81012

大阪, 大阪, 日本

联系我们

试验信息

关注试验

参与者年龄

18 岁及以上

疾病

白血病 - AML

骨髓肿瘤

参与者性别

女性和男性

试验开展时间

2019年9月 - 2023年3月

分享给

更多研究详情

入选标准

Subject diagnosed with R/R AML or R/R higher risk MDS is defined as:
- R/R AML: Morphologically documented primary or secondary AML by the WHO criteria (2016); and refractory to at least 2 cycles of induction chemotherapy/not a candidate for re-induction or relapsed after achieving remission with a prior therapy; and received all standard therapies including targeted therapies (unless the therapy is contraindicated or intolerable) which are known to provide clinical benefit in the opinion of the treating investigator; and received salvage therapy or is not a candidate for salvage therapy.
- R/R higher risk MDS: Has MDS by the WHO criteria (2016); and either relapsed after achieving remission or refractory to standard therapies, including ≥ 4 cycles of hypomethylating agents (unless the therapy is contraindicated or intolerable); and is classified as higher risk MDS with a score of > 3.5 by Revised International Prognostic Scoring System (IPSS-R) in MDS.
Subject has an Eastern Cooperative Oncology Group performance status of ≤ 2.
Subject must meet the following criteria as indicated on the clinical laboratory tests during screening period:
- Serum aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × upper limit of normal (ULN).
- Serum total bilirubin ≤ 1.5 × ULN.
- Serum creatinine ≤ 1.5 × ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.
Platelets ≥ 50,000/μL at cycle 1 day 1 (C1D1) in the dose escalation cohorts only.
Subject has a life expectancy of ≥ 12 weeks at the time of screening.
Subjects with AML must have peripheral blood absolute blast count of < 20,000/μL at C1D1. Note: Blast count can be controlled by hydroxyurea during screening period.
Female subject is not pregnant and at least 1 of the following conditions apply:
- 非有生育能力的女性 (WOCBP)。
- WOCBP who agrees to follow the contraceptive guidance from the time of informed consent through at least 180 days after final study treatment administration.
Female subject must agree not to breastfeed starting at screening and throughout the study period and for 180 days after the final study treatment administration.
Female subject must not donate ova starting at first dose of investigational product (IP) and throughout the study period and for 180 days after final study treatment administration.
Male subject with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 180 day after final study treatment administration.
Male subject must not donate sperm during the treatment period and for 180 days after the final study treatment administration.
Male subject with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 180 days after final study treatment administration.
Subject agrees not to participate in another interventional study while receiving study treatment in the present study.

排除标准

Subject was diagnosed with acute promyelocytic leukemia.
Subject has breakpoint cluster region-Abelson-positive leukemia (BCR-ABL).
Subject has persistent non-hematological toxicities of ≥ grade 2 (National Cancer Institute’s Common Terminology Criteria for Adverse Events [NCI-CTCAE], version 5.0), with symptoms and objective findings from prior AML or MDS treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation or surgery).
Subject has received any of the following therapies:
- Systemic immunomodulators or immunosuppressive drugs including steroids ≤ 28 days prior to C1D1 (steroids can be used if not intended for treatment of AML or MDS; steroids for AML/MDS related symptoms can be used at low doses [less than 10 mg/day dexamethasone]).
- Cytotoxic agents (except hydroxyurea given for controlling blast cells) ≤ 28 days prior to C1D1.
- Investigational products for the treatment of AML or MDS within 5 half-lives prior to screening visit.
- Hematopoietic stem cell transplant (HSCT).
- Radiation therapy ≤ 28 days prior to C1D1.
Subject has clinically active nervous system leukemia.
Subject has active or prior documented autoimmune or inflammatory disorders requiring systemic treatment.
Subject has ongoing, untreated malignancy with the exception of the following:
- Subjects with treated non-melanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
- Subjects with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.
Subject with left ventricular ejection fraction of < 45% on echocardiogram or multigated acquisition scan (MUGA) performed within 28 days of screening.
Subject has laboratory abnormalities, or clinical evidence of disseminated intravascular coagulation, or ongoing history of coagulation disorder manifested by bleeding or clotting.
Subject has an active uncontrolled infection.
Subject is known to have human immunodeficiency virus infection.
Subject has active hepatitis B or C or other active hepatic disorder.
Subject has any condition which makes the subject unsuitable for study participation.
Subject has a known or suspected hypersensitivity to bovine-derived protein or has suspected hypersensitivity to any ingredients of ASP7517.
Subject is eligible for HSCT.

常见问题

临床试验是否只针对晚期癌症患者？

虽然某些临床试验可能侧重于更晚期的癌症，但许多试验对处于不同癌症阶段的患者开放。每项研究都有关于参与资格的规定。例如，只有特定年龄段的患者或患有特定类型肿瘤的患者才能参与。

我是否需要停止当前治疗才能参加临床试验？

有时，研究人员希望参与者在临床试验期间继续接受当前治疗。有时，您可能需要暂停当前的治疗。如果研究性治疗无效，您通常可以恢复原有的治疗方案。

我是否应该担心会服用安慰剂？

在癌症临床试验中，只有当该类癌症尚无其他治疗方法时，才会使用安慰剂。这有助于将研究性治疗与安慰剂进行比较。安慰剂在癌症试验中很少使用，因为通常会采用最佳可用疗法，即所谓的“标准治疗方案”。

我是否需要医生转诊才能参加一项研究？

您的医生可能并不了解所有可供您参与的临床试验机会。请与您的医生或其他医疗服务提供者讨论您所找到的临床试验信息。他们可以帮助您判断临床试验是否适合您。If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

探索更多

A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)

试验摘要

更多研究详情

获取更多信息

地点

常见问题

探索更多

什么是临床试验?

为什么临床试验很重要？

为什么要参加临床试验